|Home | About | Journals | Submit | Contact Us | Français|
Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.
Acute myeloid leukemia (AML) is a heterogeneous disease with a broad spectrum of clinical presentations and heterogeneous response to therapy . According to a 2014 estimate, more than half the patients diagnosed with AML in the United States will die from the disease . A majority of AML cases are diagnosed in patients who are 65 years of age or older. The current standard of care for such patients is either conventional induction with cytarabine and an anthracycline, or treatment with a hypomethylating agent (HMA) such as decitabine or azacytidine [3, 4]. Either approach results in similar overall survival benefits and high rates of relapse. A potentially curative approach is allogeneic hematopoietic stem cell transplantation (aHSCT), which results in sustained remission in about half of eligible patients due to a graft-versus-leukemia effect . Unfortunately, aHSCT is limited to fit patients with an available donor and is associated with significant treatment-related morbidity and mortality. Nevertheless, the efficacy of aHSCT demonstrates the potential of the adaptive immune system to eradicate residual AML and provides a rationale for the development of alternative immunotherapeutic strategies .
The identification of appropriate antigens for T-cell directed immunotherapy in myeloid malignancy remains a challenge [8, 9]. CD123 and CD33 have shown some potential, but due to their co-expression on healthy hematopoietic cells, toxicity remains a significant barrier. Thus, identifying leukemia specific antigens would be a considerable advance towards solving this problem. Cancer testis antigens (CTAs) are a family of more than 200 X-linked and autosomal genes that are normally expressed in the embryonic ovary and the adult testis . In all other adult tissues, expression of CTA family genes is limited due to epigenetic silencing of their regulatory elements. Aberrant expression of CTAs due to demethylation of their promoters has been found in multiple solid tumor types. [11–14]. Early and advanced clinical trials based on vaccination against CTAs have shown clinical benefit in lung, melanoma and ovarian cancer [15–17].
The utility of CTAs as viable tumor antigens in myeloid malignancies has been less studied. In contrast to solid tumors, hypermethylation of CTA gene promoters, in association with gene silencing is observed in leukemia cell lines and in primary specimens, limiting their potential [18–21]. We and others have demonstrated that treatment of AML cell lines, both in vitro and as tumor xenografts, with HMAs induces expression of CTAs [18–21]. In contrast with solid tumors, where HMAs have demonstrated limited clinical activity, these drugs are in routine use for the management of patients with AML [3, 4]. Induced expression of CTAs following HMA therapy would offer an opportunity for immunotherapy towards cells that re-express this antigen.
In this report, we evaluated the induced expression of CTA family members in peripheral blood samples serially isolated from AML patients with active disease undergoing decitabine monotherapy. We observed significant upregulation of both New York-Esophageal Cancer-1 (NY-ESO-1) and Melanoma Antigen Family A3/6 (MAGEA3/A6), established immunogenic tumor antigens. Expression of NY-ESO-1 and MAGEA3/A6 was associated with hypomethylation of their promoter regions. NY-ESO-1 mRNA levels were increased in samples from patients who did not respond clinically to HMA therapy, suggesting that immunotherapies that recognize CTAs have the potential to benefit this population of patients for whom current therapies are limited. The induction of NY-ESO-1 expression by decitabine resulted in the presentation of antigen at sufficient levels for recognition by NY-ESO-1 specific CD8+ T-cells. Together, our data indicate that immunotherapeutic approaches directed against CTAs are feasible within the clinical context of patients receiving HMAs for myeloid malignancy.
To determine whether decitabine monotherapy resulted in CTA gene expression, we isolated RNA from serial peripheral blood samples harvested from AML patients during a first cycle of therapy. We began by examining expression of a panel of eight different CTA genes in two patients, one who had received decitabine 20mg/m2/day for 10 days and the other azacitidine at a dose of 75mg/m2/day for 7 days (Supplemental Figure 1A) [19, 20, 22, 23]. In these first two patients we observed low level mRNA induction of MAGE family members as well as NY-ESO-1 and X antigen family member 1 (XAGE1), but limited induction of PAS domain containing 1 (PASD1), Preferentially Expressed Antigen in Melanoma (PRAME) and Sperm Autoantigenic Protein-17 (SP17). We went on to examine expression of MAGEA1, MAGEA3/A6, NY-ESO-1 and XAGE1 in a larger panel of five AML patients treated with decitabine 20mg/m2/day for 5-10 days as a single agent, clinical characteristics are presented in Table Table11 (Cohort A). These patients demonstrated limited induction of MAGEA1 (1/5 patients), but 3/5 patients showed induction of XAGE1 (Supplemental Figure 1B). Induced mRNA expression of NY-ESO-1 was seen in 5/5 patients. In concordance with the observed induction of gene expression, hypomethylation of the NY-ESO-1 promoter was observed (Supplemental Figure 2). Induction of MAGEA3/A6 was observed in 3/5 patients from this cohort (Figure (Figure1A1A).
The induction of NY-ESO-1 mRNA was confirmed in a group of 7 German AML patients (Cohort B) receiving decitabine . In this cohort 5/7 sampled patients demonstrated increased expression of NY-ESO-1 mRNA (Figure (Figure1B).1B). Based upon our initial evaluation of CTA gene induction with HMAs, we elected to further examine induced NY-ESO-1 and MAGEA3/A6 expression in a larger cohort of AML patients as these genes are established tumor antigens with clinically translatable vaccines in development.
In order to confirm the results observed in our initial small cohorts of patients, we procured serially sampled peripheral blood samples from a third cohort (C) of 22 HMA naive AML patients receiving decitabine induction at a dose of 20 mg/m2/day for 10 consecutive days of a 28 day cycle. Clinical characteristics for the cohort “C” patients are presented in Table Table1.1. As a positive control for changes in global methylation we analyzed Long Interspersed Nuclear Elements-1 (LINE-1) methylation changes using sodium bisulfite pyrosequencing of peripheral blood samples harvested from a range of time periods after the start of decitabine therapy. There was a statistically significant decrease in global methylation when comparing samples obtained pre-decitabine to the nadir LINE-1 methylation value for each individual patient over time (Supplemental Figure 3). Average LINE-1 methylation decreased in samples harvested sequentially over the treatment period. A majority of patients show the expected pharmacodynamic response to decitabine treatment.
We quantified NY-ESO-1 and MAGEA3/A6 promoter methylation and mRNA levels following decitabine monotherapy using our larger cohort “C” of serial patient samples. We determined changes in NY-ESO-1 promoter methylation using sodium bisulfite pyrosequencing. We first examined the entire cohort, comparing NY-ESO-1 methylation pre-decitabine to the post-decitabine nadir time point for each patient and observed a statistically significant decrease in NY-ESO-1 promoter methylation (Figure (Figure2A).2A). Hypomethylation of the NY-ESO-1 promoter was examined during each of the time intervals as described for LINE-1 (Figure (Figure2B).2B). As expected, there was a statistically significant decrease in methylation of the NY-ESO-1 promoter in samples harvested during each post-decitabine period (days 1-5; 6-10; 11-15; 15+). Changes in NY-ESO-1 and LINE-1 methylation were significantly correlated (R2 = 0.77, p < 0.0001, Supplemental Figure 4A). Patients generally demonstrated a progressive decrease in NY-ESO-1 methylation during treatment. Representative time course data for individual patients is presented for “Cohort C” patients 6, 11 and 25 (Figure (Figure2C2C).
Prior to decitabine treatment, 18% (4/22) of samples exhibited detectable levels of NY-ESO-1 mRNA, albeit at very low level (Figure (Figure2D).2D). Following decitabine therapy, 78% (17/22) of samples had detectable levels of NY-ESO-1 mRNA. Treatment with decitabine was associated with a significant increase in NY-ESO-1 expression when comparing pre-treatment expression to the maximum expression at any time interval post decitabine. NY-ESO-1 expression was significantly increased at time points beyond day 6 (Figure (Figure2E).2E). Representative time courses for gene expression are presented for three patients in Figure Figure2F.2F. Some patients (such as Patient 6) had low to undetectable levels of NY-ESO-1 at early time points and exhibited a substantial increase in NY-ESO-1 mRNA during treatment while others (e.g. Patient 11) displayed a steady increase in NY-ESO-1 mRNA throughout the time course. Patient 25 demonstrated early induction of NY-ESO-1 mRNA which then declined to low/undetectable levels at later time points over the 28 day course. Tight correlation was not observed between NY-ESO-1 mRNA expression and NY-ESO-1 promoter methylation across the entire cohort (R2 = 0.01, p = 0.64, Supplemental Figure 4B).
Compared with NY-ESO-1, MAGEA3/A6 promoter methylation was more heterogeneous in pre-treatment AML samples. Post-decitabine there was a statistically significant decrease in MAGEA3/A6 promoter methylation when comparing baseline methylation to the post-decitabine nadir time point (Figure (Figure3A).3A). Hypomethylation of the MAGEA3/A6 promoter was also statistically significantly lower at each time interval studied following decitabine treatment (Figure (Figure3B).3B). As observed for NY-ESO-1, methylation of the MAGEA3/A6 promoter decreased progressively over the sampled time points as exemplified by cohort C patients 6,11 and 25 (Figure (Figure3C).3C). Changes in MAGEA3/A6 and LINE-1 methylation were significantly correlated (R2=0.4, p < 0.01, Supplemental Figure 4A).
Low level MAGEA3/6 mRNA expression was detected in 100% of diagnostic samples (21/21), and there was a statistically significant increase in MAGEA3/A6 expression when comparing expression pre-decitabine with the maximal expression any time point following treatment with decitabine (Figure (Figure3D).3D). Induced expression of MAGEA3/A6 was most increased at the latest time points studied (Days 15+; Figure Figure3E).3E). Expression of MAGEA3/A6 also demonstrated some time associated variability, as observed for NY-ESO-1, but a majority of patients had later induction of MAGEA3/A6 as exemplified by patients 6, 11 and 25 (Figure (Figure3F).3F). There was no correlation observed between MAGEA3/A6 promoter methylation and MAGEA3/A6 mRNA expression (R2 = 0.005, p = 0.44, Supplemental Figure 4C).
To determine whether the observed induction of CTAs was present in the AML blast population, we isolated mRNA from CD34+ and CD34- cells from peripheral blood samples. Samples for this analysis were selected based upon the known blast immunophenotype. For this analysis we focused on NY-ESO-1 expression due to sample limitations. Nested RT-PCR analysis (required due to low cell numbers, particularly in the post-treatment samples) revealed that 6 out of 8 patients analyzed exhibited NY-ESO-1 expression in CD34+ blasts following decitabine treatment (Figure (Figure4),4), indicating induction of NY-ESO-1 occurred in the AML blasts. NY-ESO-1 positivity in the CD34+ blast compartment was consistent with NY-ESO-1 positivity in the unselected bulk mononuclear cell population used for the primary analysis.
Our analysis of LINE-1 methylation indicated that the majority of patients responded to decitabine treatment at the molecular level. Hypomethylation has not, however, been tightly correlated with clinical response to decitabine [25–27]. We therefore tested whether levels of NY-ESO-1 or MAGEA3/A6 mRNA induction were different in patients who demonstrated a clinical response compared with those who did not. Overall, 7/22 patients (32%) demonstrated a clinical response to decitabine characterized according to the International Working Group (IWG) criteria for AML and MDS (CR, CRp/i or HI) [28, 29]. Sixty-eight percent of patients (15/22) did not demonstrate a clinical response, or died before a response could be evaluated. Of the 7 patients who clinically responded to decitabine, 6 demonstrated a significant increase in NY-ESO-1 mRNA (Figure (Figure5A).5A). Crucially, NY-ESO-1 mRNA levels were also significantly increased in 11 out of the 15 patients that did not demonstrate a clinical response to decitabine. Baseline levels of MAGEA3/A6 were detectable for all the patients studied in Cohort C and there were no statistically significant difference in MAGE A3/A6 expression following decitabine for responders or non-responders (Supplemental Figure 5A). Changes in MAGEA3/A6 methylation were also not different between responders and non-responders to decitabine (Supplemental Figure 5B).
We compared NY-ESO-1 promoter methylation and LINE-1 methylation with induction of NY-ESO-1 expression as a categorical variable in both clinical responders and non-responders. Although discrepancies in group sizes preclude us from making a direct comparison using statistical analysis, there appears to be a trend towards lower NY-ESO-1 promoter methylation in those patients that demonstrated higher levels of NY-ESO-1 mRNA following decitabine in both clinical responders and non-responders (Figure (Figure5B5B and and5C).5C). Interestingly, post decitabine LINE-1 methylation levels were generally lower (mean change −18.3%) among responders than among non-responders (mean change −12.7%), but this was not a statistically significant difference.
In addition to their ability induce the expression of potentially tumor associated antigens like NY-ESO-1 and MAGEA3/A6, HMAs have been shown to have effects on the induction of co-stimulatory and immunoregulatory molecules on cancer cells, potentially enhancing their recognition by the immune system. We and others have demonstrated that in vitro exposure to HMAs can increase levels of MHC class I and the costimulatory molecules CD80 and CD86 [18, 30, 31]. Furthermore changes in expression of the immune checkpoint inhibitor PD-L1 in samples exposed to HMAs have been reported . Finally, alterations in antigen processing, such as downregulation of Transporter Associated with Antigen Processing 1 (TAP1) expression, have been reported in a variety of different cancer types and have been shown to limit antigen recognition by the immune system . To test whether decitabine has an effect on expression of any of these immune regulatory molecules, we performed flow cytometry on viably frozen peripheral blood blasts harvested from Cohort C patients between days 4 and 10 after the start of decitabine. In agreement with previous reports, we observed a trend toward increased levels of the MHC Class I molecules HLA-ABC in AML blasts after decitabine treatment compared to the level pre-decitabine (p < 0.06; Supplemental Figure 5A) . We also examined expression of the MHC Class II molecule HLA-DR, but did not observe significant changes in its expression (Supplemental Figure 6A). There were likewise no significant changes in the expression of the co-stimulatory molecules CD80 and CD86 following decitabine exposure (Supplemental Figure 6B). It is important to note that due to limitations of sample availability, these data represent a single follow up time point for each patient and are therefore potentially limited by time point selection. In contrast with previous reports, expression of PD-L1 was frequent on AML blasts both before and after treatment with decitabine and did not appear to be substantially changed following exposure to decitabine (Supplemental Figure 6B).
Previous studies demonstrated that the TAP1 gene, which participates in antigen processing, has a CpG island and is frequently methylated in cancer [34, 35]. Therefore, we tested whether TAP1 mRNA levels were increased in patients’ samples following decitabine therapy. Individual samples collected from patients undergoing decitabine treatment exhibited a modest increase in TAP1 mRNA levels compared to their diagnostic sample, but overall, we did not observe a significant increase in TAP1 mRNA levels (Supplemental Figure 6C).
Although we observed a consistent increase in NY-ESO-1 mRNA levels in the circulating blasts of Cohort C patients treated with decitabine, this low-level mRNA expression does not necessarily translate into a level of protein expression sufficient to trigger recognition and cell killing by antigen specific T cells. We demonstrated detectable NY-ESO-1 protein by immunoblotting on selected patient samples following decitabine therapy, but a majority of patients with detectable NY-ESO-1 expression did not demonstrate protein expression by western blot (Supplemental Figure 7). We sought to determine whether AML blasts with variable degrees of NY-ESO-1 mRNA expression were producing sufficient protein expression (below the level of detection by immunoblotting) to allow for recognition by HLA compatible NY-ESO-1 specific CD8+ T-cells. HLA-A*0201 restricted NY-ESO-1-specific CD8+ T cells were obtained from an ovarian cancer patient vaccinated against NY-ESO-1 on a clinical study as previously described . Samples with higher and lower NY-ESO-1 mRNA expression were used to determine if a threshold of expression was required for T-cell recognition were selected based upon HLA-A*0201 expression by HLA typing. We stimulated NY-ESO-1- specific CD8+ T cells with AML blasts isolated from 4 HLA-A*0201+ AML patients before and after decitabine treatment. The mRNA levels of NY-ESO-1 in these patients are presented in Figure Figure6A;6A; 3 of the 4 patients included in this analysis had no detectable NY-ESO-1 protein by immunoblotting. T-cell responses were determined by intracellular cytokine staining for IFNγ, TNFα and IL-2 in NY-ESO-1157-165 tetramer-positive CD8+ T-cells. We also quantified the expression of CD107a/b, which is a surrogate marker for the cytotoxic activity of T-lymphocytes. A representative example of the flow cytometry analysis for one patient is shown in Figure Figure6B.6B. As a positive control for T-cell activation, expression of these markers following non-specific T-cell activation with phorbol 12-myristate 13-acetate (PMA)/ionomycin is shown in Figure Figure6C.6C. Following co-culture with AML blasts harvested post-decitabine, we observed an increase in the levels of IFN-γ, TNF-α, IL-2, and CD107a/b in HLA-A*0201/NY-ESO-1157-165 tetramer+ CD8+ T-cells in three of four patients studied, compared to T-cells co-cultured with AML blasts obtained prior to decitabine exposure (Figure (Figure6B6B and and6D).6D). These data indicate that peripheral blood blasts harvested from patients receiving standard of care decitabine as induction therapy present sufficient quantities of NY-ESO-1 protein to result in a response from HLA compatible NY-ESO-1-specific CD8+ T cells.
CTA-directed immunotherapy has been employed against tumors that constitutively express CTA genes [15–17]. We and others have demonstrated that several tumor types, including AML, show low to variable transcription of CTA genes due to promoter hypermethylation; exposure to HMAs increases mRNA and protein levels of CTA family members [18–21]. In this report, we have extended our prior findings by demonstrating that AML patients at two separate institutions receiving standard doses and schedules of decitabine exhibit increased mRNA and protein levels of the CTA genes NY-ESO-1 and MAGEA3/A6 in circulating blasts. Critically, our data indicate that decitabine treatment results in AML cells that express NY-ESO-1 at levels sufficient for recognition by antigen specific T cells.
We observed variation in both the magnitude and the kinetics of CTA induction in response to decitabine. Although it is possible that is partly due to variation among patients in their individual response to decitabine, our data demonstrating a significant decrease in LINE-1 methylation suggests that a majority of patients exhibited a pharmacodynamic response to decitabine. There were significant correlations between demethylation of LINE-1 and demethylation of NY-ESO-1 and MAGEA3/A6, further supporting the interpretation that variance in the mRNA levels of NY-ESO-1 and MAGEA3/A6 are not solely due to insufficient demethylation. Although we did not observe a significant correlation between promoter methylation and mRNA level for either NY-ESO-1 or MAGEA3/A6, similar findings have been made in other contexts, suggesting that mechanisms in addition to DNA methylation control expression of these genes [37–39].
There was no apparent association between induction of NY-ESO-1 and clinical response. The majority of patients who did not respond to decitabine still exhibited an increase NY-ESO-1 mRNA. The sample size of this cohort does not have sufficient power to determine whether clinical responders exhibit higher or more frequent induction of CTA expression compared to clinical non-responders. Our data indicating that NY-ESO-1 induction is observed in a majority of clinically non-responsive patients suggest the intriguing possibility that immunotherapies that recognize NY-ESO-1 have the potential to be effective even in patients who do not respond to decitabine alone.
Our data suggesting an overall trend towards increased levels of HLA Class I molecule expression on AML blasts following decitabine therapy is supported by studies published by our group and others demonstrating that HMAs induce HLA Class I expression in leukemia and other tumor cell lines [18, 31]. The functional significance of this result is still unclear and further work is required to test the hypothesis that HMAs enhance antigen presentation.
Several authors have demonstrated enhanced expression of PD-L1 and a T-cell exhaustion phenotype within the context of disease progression in AML, both in mouse models as well as in primary patient samples [40–43]. Patients with myeloid malignancy treated with HMAs have been shown to have increased expression of checkpoint inhibitory molecules within the malignant cellular compartment, and HMAs may also produce hypomethylation of the PD-1 promoter in circulating lymphocytes [32, 44]. PD-L1 expression was common in our patient samples both before and after treatment with decitabine. Several immunotherapeutic approaches using CTAs, including vaccination and adoptive transfer of T-cells with engineered T-cell receptors or chimeric antigen receptors, have been reported [16, 17, 36, 45–47]. Taken together our data support the hypothesis that combinations of CTA directed vaccination, an HMA and a checkpoint inhibitor might be an attractive approach for patients with AML .
Two cohorts of AML patients (“A” and “C”) receiving decitabine monotherapy were enrolled under an Institutional Review Board approved protocol at the Roswell Park Cancer Institute (RPCI). Bone marrow and peripheral blood samples were collected prior to decitabine treatment and peripheral blood samples were collected serially two to four times per week during their first cycle of decitabine therapy (20 mg/m2 per day for 10 days). Mononuclear cells were separated and cryopreserved following Ficoll centrifugation. A third cohort of patients (“B”) was treated at the University of Freiberg Medical Center and samples were collected with approval of the Ethics Committee . Clinical characteristics of patients are shown in Table Table11 and were previously published in Claus, et al. .
Absolute quantification of RNA was performed using PCR Master Mix for SYBR Green assays (Eurogentec, Fremont, CA) for MAGEA3/6 and Taqman probe assay for NY-ESO-1-Hs00265824_m1 and 18s rRNA (cat no-4319413E) (Life Technologies, Carlsbad, CA) on the 7300 Real-Time PCR System (Applied Biosystems, Carlsbad, CA). All samples were run in duplicate, and NY-ESO-1 and MAGEA3/6 gene expression data were normalized to GAPDH or 18S rRNA. Primer sequences for NY-ESO-1, MAGEA3/A6, and 18S rRNA have been previously described . Primer sequences for other CTA genes are as follows: MAGEA1 (Forward: GCACCTCTTGTATCCTGGAGTC; Reverse: GACACTCTCCAGCATTTCTGCC); MAGEB2 (Forward: GAACCCTGGAAGCTCATCACCA; Reverse: GCTGGTTTCAGCATAGGCTCTC); PASD1 (Forward: GAAGAGAGGACTTGGTTGCTGC; Reverse: GGAGATCAGGAATGACAACGTGG); PRAME (Forward: ACCTGGAAGCTACCCACCTT; Reverse: AGATGCATCACATCCCCTTC); SP17 (Forward: GGAGTAAGGTAGAAGACCGCTTC; Reverse: TGGTGACTGATGTCTCTTCCTCC); XAGE1 (Forward: ACCACACAGCCAGTCCCAGGAGCC; Reverse: AACCAGCTTGCGTTGTTTCAGCTTG). GAPDH primers (Forward:TGAAGGTCGGAGTCAACGGA; Reverse:CCATTGATGACAAGCTTCCCG).
Relative quantification of TAP-1 mRNA levels were determined using the 2−ΔΔCT method as previously described  and were measured using the Hs_TAP1_QF_1 QuantiFast Probe Assay (Qiagen, Valencia, CA) and normalized to 18S rRNA.
Whole protein was extracted and quantitated as previously described . 30-100 μg of protein was loaded onto a NuPAGE® Novex® 4-12% Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose membrane (Invitrogen). 5% blotting grade blocker (Bio-Rad, Hercules, CA) in phosphate-buffered saline was used to block nonspecific binding. Membranes were incubated overnight at 4°C with NY-ESO-1 (Invitrogen, clone E978) or MAGE-A antibodies (Invitrogen, clone 6C1) at 1:200, then incubated with secondary antibody (GE Healthcare Life Sciences, Piscataway, NJ) at 1:3000 dilution for 1hr. β-actin antibody (MP Biomedicals, Santa Ana, CA, clone C4) at 1:10,000 dilution was used as a loading control. Proteins were visualized using an enhanced chemiluminescence detection kit (GE Healthcare Life Sciences). As a positive control for NY-ESO-1 expression, we used protein derived from OVCAR-3 cells treated with decitabine as previously described .
The All Prep DNA/RNA Mini kit (Qiagen) was used to isolate genomic DNA and sodium bisulfite conversion was performed using the EZ DNA Methylation Kit (Zymo Research, Irvine CA). Methylation of the NY-ESO-1 and MAGEA3/A6 promoters and the LINE-1 repetitive elements was determined by sodium bisulfite pyrosequencing as previously described [51, 52].
CD34 positive and negative cells were isolated from peripheral mononuclear cells using CD34 Microbeads as per manufacturer instructions (Miltenyi Biotec). RNA and cDNA was prepared as described earlier . NY-ESO-1 nested PCR was performed by performing two PCR reactions: PCR-1 (Forward: 5′-CAGGGCTGAATGGATGCTGCAGA-3′ and Reverse: 5′-GCGCCTCTGCCCTGAGGGAGG-3′; amplifying a 332 bp product) followed by PCR-2 (Forward: 5′-GGCTGAATGGATGCTGCAGA-3′ and Reverse: 5′-CGGACACAGTGAACTCCTTC-3′; amplifying 177 bp product) [18, 53]. GAPDH primers sequences are as mentioned earlier. PCR products were amplified with initial denaturation at 95°C for 5 min, then 35 cycles of denaturation at 95°C for 30 sec., annealing at 60°C for 30 sec., and extension at 72°C for 30 sec., followed by a final 5 min extension at 72°C. PCR products were analyzed on 2% agarose gel by ethidium bromide staining.
Cells were stained with mouse anti-human CD34 (Allophycocyanin (APC)-conjugated, clone 4H11; eBioscience, San Diego, CA), HLA-DR (Brilliant Violet (BV) 711-conjugated, clone L243; BioLegend, San Diego, CA), HLA-A,B,C (APC-Cy7-conjugated, clone W6/32; BioLegend), PD-L1 (Phycoerythrin (PE) -conjugated, clone 29E.2A3; BioLegend), CD80 (BV650-conjugated, clone 2D10; BioLegend), and CD86 (BV605-conjugated, clone IT2.2; BioLegend). Live cells were determined by staining cells with 4′,6-diamidino-2-phenylindole (DAPI) and were defined as DAPI-negative. Cells were analyzed using an LSRII (Becton Dickinson, Franklin Lakes, NJ) and raw data were analyzed using FlowJo v.9.5.2 software (TreeStar, Ashland, OR).
NY-ESO-1-specific HLA-A*0201-restricted CD8+ T cells were co-cultured with HLA-A*0201 bone marrow or peripheral blood mononuclear cells pre and post-decitabine treatment from AML patients for 6 hr at 37°C in the presence of anti-CD107a (clone H4A3) and CD107b (clone H4B4) . Monensin and brefeldin A were added during the last 4 hr of incubation to block cytokine secretion. Cells were fixed with 2% formaldehyde, followed by permeabilization staining with IFNγ (clone B27), TNFα (clone MAb11) and IL-2 (clone MQ1-17H12) in the presence of normal mouse IgG and permeabilization buffer (Invitrogen-Caltag). Negative and positive control stimulations with and without peptide (NY-ESO-1157-165) or PMA and ionomycin were set up in parallel.
All statistical analyses were performed using GraphPad Prism 6. For all experiments, p-values were determined using non-parametric Wilcoxon signed rank tests or Spearman rank correlations, p values < 0.05 were deemed significant.
The authors thank Brandon Martens and Linda Lutgen-Dunckley from the Leukemia Procurement Bank at Roswell Park Cancer Institute for procuring primary AML samples. The authors also thank the patients without whom this work would not be possible. This study used shared resources supported by RPCI's Cancer Center Support Grant from the NCI (P30CA016056).
CONFLICTS OF INTEREST
The author(s) declare that they have no conflict of interests
This work was supported by the Louis M. Sklarow Foundation (to EAG), the Bauer Family Foundation (to EAG), Alliance Developmental Awards from the Roswell Park Alliance Foundation (to EAG and MJN), NCI Cancer Center Support Grant CA016056, Institutional National Research Service Award 5T32CA009072-39 (BEP), The German Research Foundation SPP1463 (N B-D and ML) and by institutional funds provided by Roswell Park Cancer Institute (MJN and EAG).